We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against other ...

Safety and simplicity of procedure has differentiated Inari versus peers (aspiration won't work in DVT). PE requires a minimum 2 year clinical trial before getting FDA-cleared (more likely 3 years).

Inari Medical stated that a significant percentage of DVT and PE patients are treated using conservative medical management that involves anticoagulants alone, which do not break down or remove an ...

Stryker plans to acquire Inari Medical in a deal valued at $4.9 billion and designed to strength its position in the peripheral vascular market. The deal, announced Monday and approved by both ...

The Cambridge-based seed design company also raised one of the largest venture capital rounds for Massachusetts tech companies in 2024. Amid frozen exit market, Flagship-founded agtech unicorn ...

Inari has developed products from the ground up with a specific ... including for treatment of pulmonary embolism (PE) and clots in transit in the right atrium. The company believes its total ...